Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00391729 · ClinicalTrials.gov registry record · Phase 2

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Phase 2 study of Attention Deficit/Hyperactivity Disorder, sponsored by Abbott.

Completed
Registry status
Phase 2
Development phase
221
Enrollment target
20
Study locations

NCT00391729 is a Phase 2 study of Attention Deficit/Hyperactivity Disorder that has completed, run by Abbott. The registered enrollment target is 221 participants, below the 283-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00391729, a Phase 2 study of Attention Deficit/Hyperactivity Disorder, has completed, sponsored by Abbott.

COMPLETED
Registry status
Phase 2
Development phase
221 participants
Enrollment target
20
Study locations

Study Summary

The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.

Conditions Studied

Attention Deficit/Hyperactivity Disorder

Interventions

  • DRUG Placebo
  • DRUG ABT-089

Study Locations (20)

Florida

  • - Jacksonville
  • - Maitland
  • - Miami
  • - Tampa

California

  • - Lafayette
  • - Oceanside
  • - San Diego

New York

  • - New York
  • - Staten Island

Arizona

  • - Mesa

Colorado

  • - Denver

Kansas

  • - Newton

Michigan

  • - Farmington Hills

Nebraska

  • - Omaha

Trial Details

FieldValue
Enrollment Target 221 participants
Start Date 2006-10
Est. Completion 2007-06
Phase Phase 2

Sponsor

Abbott

181 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00391729

The ClinicalTrials.gov registry entry for NCT00391729 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 283-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (22% lower). The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Attention Deficit/Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00391729 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT00391729 about?

NCT00391729 is a clinical study titled "A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.

What is the current status of trial NCT00391729?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2006-10. Estimated completion is 2007-06.

What conditions does trial NCT00391729 study?

This clinical trial studies the following conditions: Attention Deficit/Hyperactivity Disorder.

What interventions are being tested in trial NCT00391729?

The interventions under investigation include: Placebo (DRUG), ABT-089 (DRUG).

Who is sponsoring clinical trial NCT00391729?

This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00391729 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Attention Deficit/Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Attention Deficit/Hyperactivity Disorder

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.